Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO.

Area of Science:

• Immunology
• Hematology

Background:

• Immune Thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts.
• The role of anti-TPO receptor (anti-c-Mpl) antibodies in ITP pathogenesis and treatment response is not fully understood.

Purpose of the Study:

• To investigate the prevalence and impact of anti-c-Mpl antibodies in ITP patients.
• To assess the association of anti-c-Mpl antibodies with disease severity, platelet counts, and response to recombinant human thrombopoietin (rhTPO) therapy.

Main Methods:

• Serum samples from 187 ITP patients and 59 healthy controls were analyzed for anti-c-Mpl autoantibodies and TPO levels.
• IgG from anti-c-Mpl antibody-positive and -negative ITP patients was used in in vitro assays to evaluate megakaryocyte proliferation, polyploidy, apoptosis, and platelet release in response to rhTPO.

Main Results:

• Anti-c-Mpl antibodies were detected in 54/187 (28.9%) ITP patients, with none found in controls.
• ITP patients with anti-c-Mpl antibodies exhibited higher serum TPO levels, lower megakaryocyte and platelet counts, and a reduced response to rhTPO treatment.
• In vitro studies showed impaired megakaryopoiesis and platelet generation in the presence of anti-c-Mpl antibodies and rhTPO.

Conclusions:

• The presence of anti-c-Mpl antibodies is associated with a poor prognosis in ITP.
• Anti-c-Mpl antibodies may serve as a predictive biomarker for rhTPO treatment unresponsiveness.
• Targeting anti-c-Mpl antibodies could represent a novel therapeutic strategy for ITP.